News Conference News ESC 2019 New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL Michael O'Riordan September 05, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Daily News Familial Hypercholesterolemia Seen in 10% of Young MI Patients Michael O'Riordan May 15, 2019
News Daily News PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction Michael O'Riordan April 29, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Daily News Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable Shelley Wood February 12, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019
News Daily News AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline Michael O'Riordan January 29, 2019
News Conference News AHA 2018 New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening Michael O'Riordan November 10, 2018
News Daily News Price Chop for Evolocumab: PCSK9 Inhibitor Cost Cut by 60% Michael O'Riordan October 25, 2018
News Features The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine Shelley Wood October 22, 2018
News Conference News EAS 2018 EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms Yael L. Maxwell May 11, 2018
News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Yael L. Maxwell May 07, 2018
News Daily News The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis Michael O'Riordan April 20, 2018
News Daily News Nonstatin Use and Expenditures Are Up Despite the Dearth of Evidence Supporting Efficacy Yael L. Maxwell January 29, 2018